Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000027795
JPRN-UMIN000027795
Not yet recruiting
未知

The phaseII study of the efficacy of Abirateron acetate and Dutasteride therapy for castration resistant prostate cancer. - The efficacy of Abirateron and Dutasteride for CRPC.

Department od Urology, Yamaguchi Graduate School of Medicine0 sites20 target enrollmentJuly 1, 2017
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionscastration resistant prostate cancer

Overview

Phase
未知
Intervention
Not specified
Conditions
castration resistant prostate cancer
Sponsor
Department od Urology, Yamaguchi Graduate School of Medicine
Enrollment
20
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2017
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Department od Urology, Yamaguchi Graduate School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\)Patients took 5alpha\-reductase inhibitors previously 2\)AST \>101 IU/L or ALT\>101 IU/L or Child\-Pugh score C 3\)HbA1c \> 10% 4\)serum potassium \< 3\.5 mEq/l

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Abiraterone with Different Steroid Medications Regimens for side effect prevention in [metastatic castrate-resistant] prostate cancer patients prior to chemotherapy treatment
EUCTR2012-004331-23-GBJanssen-Cilag International NV164
Active, not recruiting
Phase 1
Abiraterone with Different Steroid Medications Regimens for side effect prevention in [metastatic castrate-resistant] prostate cancer patients prior to chemotherapy treatmentMetastatic Castration-Resistant Prostate CancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-004331-23-HUJanssen-Cilag International NV144
Active, not recruiting
Phase 1
Abiraterone with Different Steroid Medications Regimens for side effect prevention in [metastatic castrate-resistant] prostate cancer patients prior to chemotherapy treatmentMetastatic Castration-Resistant Prostate CancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-004331-23-BEJanssen-Cilag International NV144
Active, not recruiting
Phase 1
A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-Naïve and Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
EUCTR2012-004331-23-ITJanssen-Cilag International NV164
Active, not recruiting
Phase 1
Abiraterone with Different Steroid Medications Regimens for side effect prevention in [metastatic castrate-resistant] prostate cancer patients prior to chemotherapy treatmentMetastatic Castration-Resistant Prostate CancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-004331-23-DEJanssen-Cilag International NV164